Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Akinori Nozawa is active.

Publication


Featured researches published by Akinori Nozawa.


Journal of Hepato-biliary-pancreatic Sciences | 2014

Case series of 17 patients with cholangiocarcinoma among young adult workers of a printing company in Japan.

Shoji Kubo; Yasuni Nakanuma; Shigekazu Takemura; Chikaharu Sakata; Yorihisa Urata; Akinori Nozawa; Takayoshi Nishioka; Masahiko Kinoshita; Genya Hamano; Hiroaki Terajima; Gorou Tachiyama; Yuji Matsumura; Terumasa Yamada; Hiromu Tanaka; Shoji Nakamori; Akira Arimoto; Norifumi Kawada; Masahiro Fujikawa; Hiromitsu Fujishima; Yasuhiko Sugawara; Shogo Tanaka; Hideyoshi Toyokawa; Yuko Kuwae; Masahiko Ohsawa; Shinichiro Uehara; Kyoko Kogawa Sato; Tomoshige Hayashi; Ginji Endo

An outbreak of cholangiocarcinoma occurred among workers in the offset color proof‐printing department at a printing company in Japan. The aim of this study was to clarify the characteristics of the patients with cholangiocarcinoma.


Journal of Occupational Health | 2014

Changes in Laboratory Test Results and Diagnostic Imaging Presentation before the Detection of Occupational Cholangiocarcinoma

Shoji Kubo; Shigekazu Takemura; Chikaharu Sakata; Yorihisa Urata; Takayoshi Nishioka; Akinori Nozawa; Masahiko Kinoshita; Genya Hamano; Yasuni Nakanuma; Ginji Endo

Changes in Laboratory Test Results and Diagnostic Imaging Presentation before the Detection of Occupational Cholangiocarcinoma: Shoji KUBO, et al. Department of Hepato‐Biliary‐Pancreatic Surgery, Osaka City University Graduate School of Medicine—


Hepatology Research | 2012

Effect of interferon therapy on first and second recurrence after resection of hepatitis C virus-related hepatocellular carcinoma

Masayuki Sakae; Shoji Kubo; Shigekazu Takemura; Chikaharu Sakata; Takahiro Uenishi; Shintaro Kodai; Hiroji Shinkawa; Yorihisa Urata; Kazunori Ohata; Kazuhisa Kaneda; Takayoshi Nishioka; Akinori Nozawa; Shigefumi Suehiro

Aim:  Several investigators have shown that interferon (IFN) therapy can suppress the recurrence of hepatocellular carcinoma (HCC) after curative treatment. We investigated the effect of IFN therapy on the first and second HCC recurrence following hepatic resection of hepatitis C virus (HCV)‐related HCC.


World Journal of Gastroenterology | 2015

Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma.

Shoji Kubo; Shigekazu Takemura; Shogo Tanaka; Hiroji Shinkawa; Takayoshi Nishioka; Akinori Nozawa; Masahiko Kinoshita; Genya Hamano; Tokuji Ito; Yorihisa Urata

Although liver resection is considered the most effective treatment for hepatocellular carcinoma (HCC), treatment outcomes are unsatisfactory because of the high rate of HCC recurrence. Since we reported hepatitis B e-antigen positivity and high serum hepatitis B virus (HBV) DNA concentrations are strong risk factors for HCC recurrence after curative resection of HBV-related HCC in the early 2000s, many investigators have demonstrated the effects of viral status on HCC recurrence and post-treatment outcomes. These findings suggest controlling viral status is important to prevent HCC recurrence and improve survival after curative treatment for HBV-related HCC. Antiviral therapy after curative treatment aims to improve prognosis by preventing HCC recurrence and maintaining liver function. Therapy with interferon and nucleos(t)ide analogs may be useful for preventing HCC recurrence and improving overall survival in patients who have undergone curative resection for HBV-related HCC. In addition, reactivation of viral replication can occur after liver resection for HBV-related HCC. Antiviral therapy can be recommended for patients to prevent HBV reactivation. Nevertheless, further studies are required to establish treatment guidelines for patients with HBV-related HCC.


Surgery | 2015

Late-onset bile leakage after hepatic resection

Masaki Kaibori; Junzo Shimizu; Michihiro Hayashi; Takuya Nakai; Morihiko Ishizaki; Kosuke Matsui; Yong Kook Kim; Fumitoshi Hirokawa; Yasuyuki Nakata; Takehiro Noda; Keizo Dono; Akinori Nozawa; Masanori Kwon; Kazuhisa Uchiyama; Shoji Kubo

BACKGROUND Postoperative bile leakage can be a serious complication after hepatic resection. Few studies have analyzed patients according to the time of onset of bile leakage. We analyzed differences between patients with early- and late-onset bile leakage after hepatic resection and assessed clinical characteristics and outcomes in patients with late-onset leakage. METHODS Between 2008 and 2010, 1,009 patients underwent hepatic resection at 4 participating university hospitals and 2 community hospitals. Fifty-two patients (5.1%) with postoperative bile leakage were divided into an early-onset group (<2 weeks after surgery, n = 34) and a late-onset group (≥2 weeks after surgery, n = 18). Patient characteristics and outcomes were collected prospectively and analyzed retrospectively. RESULTS The proportion of patients who underwent intra-abdominal placement of a drainage catheter was significantly less in the late-onset group than the early-onset group. All 18 patients in the late-onset group developed intra-abdominal infection, and 2 died of sepsis. The proportion of patients who underwent invasive treatment (abdominal paracentesis, endoscopic biliary drainage, or second hepatic resection) was significantly greater in the late-onset group than in the early-onset group. The time to resolution of bile leakage was significantly greater in the late-onset group than the early-onset group. CONCLUSION Patients should be monitored carefully for bile leakage for several weeks after hepatic resection, because late-onset bile leakage can cause serious complications. Intra-abdominal infection should also be treated as soon as possible, because it may induce refractory bile leakage with serious complications.


Journal of Hepato-biliary-pancreatic Sciences | 2012

Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma

Yorihisa Urata; Shoji Kubo; Shigekazu Takemura; Takahiro Uenishi; Shintaro Kodai; Hiroji Shinkawa; Masayuki Sakae; Kazuhisa Kaneda; Kazunori Ohata; Akinori Nozawa; Shigefumi Suehiro


Surgery Today | 2013

Nutritional risk index as an independent predictive factor for the development of surgical site infection after pancreaticoduodenectomy

Hiroji Shinkawa; Shigekazu Takemura; Takahiro Uenishi; Masayuki Sakae; Kazunori Ohata; Yorihisa Urata; Kazuhisa Kaneda; Akinori Nozawa; Shoji Kubo


Surgery Today | 2015

Hepatic resection for hepatocellular carcinoma in super-elderly patients aged 80 years and older in the first decade of the 21st century

Akinori Nozawa; Shoji Kubo; Shigekazu Takemura; Chikaharu Sakata; Yorihisa Urata; Takayoshi Nishioka; Masahiko Kinoshita; Genya Hamano; Takahiro Uenishi; Shigefumi Suehiro


Pancreatology | 2016

Repeat pancreatectomy for remnant pancreatic cancer: Report of 4 cases

Sadatoshi Shimizu; Akihiro Murata; Akishige Kanazawa; Shintaro Kodai; Yorihisa Urata; Akinori Nozawa; Jun Tauchi; Shigeaki Kurihara; Tetsuzo Tashima; Sota Deguchi; Syuhei Kushiyama


Pancreatology | 2016

A case of pancreatic ductal adenocarcinoma with squamous component, difficult to distinguish from pancreatic metastasis of ureteral cancer

Syuhei Kushiyama; Akihiro Murata; Sadatoshi Shimizu; Akishige Kanazawa; Shintaro Kodai; Yorihisa Urata; Akinori Nozawa; Jun Tauchi; Shigeaki Kurihara; Tetsuzo Tashima; Sota Deguchi; Hiroko Nebiki; Yuko Fukushima

Collaboration


Dive into the Akinori Nozawa's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge